News Pfizer takes pipeline blow as it abandons cardiomyopathy dru... Pfizer has stopped development of a drug to treat cardiomyopathy caused by a rare form of heart disease, after it proved ineffective in a phase 3 trial.
News As Lyrica patent expiry looms, Pfizer buys Array for $11.4bn Pfizer has a made a $48 per share play for Array Biopharma, which values the cancer specialist at $11.4 billion.
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face